New pain block could cut opioid use after mastectomy

NCT ID NCT07562945

First seen May 03, 2026 · Last updated Jun 20, 2026 · Updated 8 times

Summary

This study tests whether a continuous nerve block using the numbing drug ropivacaine can reduce pain, inflammation, and opioid use in women undergoing mastectomy for breast cancer. Forty women will be randomly assigned to receive the nerve block or standard pain care. Researchers will measure pain scores, opioid consumption, and markers of inflammation in the first 24 hours after surgery.

Disclaimer Read more

This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for BREAST CANCER are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Contacts and locations

Study contacts

  • Contact

    Phone: •••-•••-•••• Email: •••••@•••••

  • Contact

    Phone: •••-•••-•••• Email: •••••@•••••

Locations

  • Ngoerah Hospital

    Denpasar, Bali, 80113, Indonesia

    Contact Phone: •••-•••-•••• Email: •••••@•••••

What this could mean

Our plain-language read of the trial. This is informational only — not medical advice or a prediction.

Active substance

ropivacaine

What this could lead to

If it works, this could offer a better way to manage pain after mastectomy, reducing the need for opioids and possibly improving recovery.

What could go wrong

This is a small, early-stage trial with only 40 participants, so results may not apply to everyone. The nerve block carries rare risks like infection or allergic reaction.

Conditions

The condition(s) this trial relates to.

breast neoplasm Pain, Postoperative

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.